Menstrual Cups Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Menstrual Cups Market
The menstrual cups size was valued at USD 1.43 billion in 2023, and the market is now projected to grow from USD 1.50 billion in 2024 to USD 2.48 billion by 2032, exhibiting a CAGR of 6.5% during the forecast period of 2024-2032.
The COVID-19 pandemic initially disrupted the menstrual cup marketplace due to deliver chain disruptions and shortages. However, as regulations eased in past due 2021, reputation for natural and reusable menstrual products grew, leading to a resurgence in market increase in 2021 and 2022.
The worldwide adoption of menstrual cups has been step by step developing, pushed through way of developing cognizance amongst girls of their benefits. Manufacturers are innovating to decorate comfort and offer customized alternatives with various styles and sizes. Factors like cost-effectiveness, sustainability, and luxury similarly raise name for, contributing to marketplace boom.
Menstrual cups provide a sustainable technique to menstrual hygiene, notably decreasing waste as compared to disposable pads and tampons. With their reusable nature lasting as lots as 12 months. They reduce environmental effect and make contributions to green menstrual practices.
Comprehensive Analysis Menstrual Cups Market
The menstrual cups growth is rising at an exponential rate due to its market segmentation. This market expansion effectively provides a detailed regional assessment considering the dominant supply and demand forces that impact the industry. These segmentations are methodically segregated By Type Analysis, By Material Type Analysis, By Distribution Channel Analysis. By Type Analysis include, with reusable and disposable product. By Material Type Analysis include, silicone, latex, and thermoplastic elastomer, By Distribution Channel Analysis include, hospital pharmacies, retail pharmacies & drug stores, and online pharmacies.
North America region lead the menstrual cups market share by benefitting a market size of USD 0.70 billion in 2023 due to the increasing adoption rate of menstrual hygiene products in North America is fueled by both the availability of a wide range of products and high awareness among women in the region.
The top gamers inside the market play a critical role in the industry assuring market boom and placing marketplace standards. These players include Sirona Hygiene, Procter & Gamble, Mooncup Ltd, Redcliffe Hygiene, Diva International, CS Technologies, Anigan, Me Luna, The Flex Company, Ruby Cup, Fleurcup, INTIMINA, Saalt. These market players provide a level playing competitive landscape.
In December 2023, The Flex Company's acquisition of All bodies Inc. and their sales of over 130.0 million units since 2016 have propelled them to surpass menstrual cups in U.S. sales, marking a significant milestone in women's health.
Segmentation Table
REPORT SCOPE & SEGMENTATION
ATTRIBUTE DETAILS
Study Period 2019-2032
Base Year 2023
Estimated Year 2024
Forecast Period 2024-2032
Historical Period 2019-2022
Unit Value (USD Billion)
Growth Rate CAGR of 6.5% from 2024-2032
Segmentation By Type
Disposable
Reusable
By Material Type
Silicone
Latex
Thermoplastic Elastomer
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies & Drug Stores
Online Pharmacies
By Region
North America
- U.S. (By Type)
- Canada (By Type)
Europe
- Germany (By Type)
- U.K. (By Type)
- France (By Type)
- Italy (By Type)
- Spain (By Type)
- Scandinavia (By Type)
- Rest of Europe (By Type)
Asia Pacific
- China (By Type)
- Japan (By Type)
- India (By Type)
- Australia (By Type)
- Southeast Asia (By Type)
- Rest of Asia Pacific (By Type)
Rest of the World
Please Note: It will take 5-6 business days to complete the report upon order confirmation.
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
- 4. Key Insights
- 4.1. Prevalence of Chronic Diseases, by Key Countries/Regions, 2022/2023
- 4.2. Pipeline Analysis, By Key Players
- 4.3. Technological Advancements
- 4.4. New Product Launches, By Key Players
- 4.5. Key Industry Developments: Mergers, Acquisitions & Partnerships
- 4.6. Impact of COVID-19 on the Market
- 5. Global CAR-T Cell Therapy Market Analysis, Insights and Forecast, 2019-2032
- 5.1. Market Analysis, Insights and Forecast – By Drug Type
- 5.1.1. Axicabtagene Ciloleucel (Yescarta)
- 5.1.2. Brexucabtagene Autoleucel (Tecartus)
- 5.1.3. Ciltacabtagene Autoleucel (Carvykti)
- 5.1.4. Idecabtagene Vicleucel (Abecma)
- 5.1.5. Lisocabtagene Maraleucel (Breyanzi)
- 5.1.6. Tisagenlecleucel (Kymriah)
- 5.1.7. Others
- 5.2. Market Analysis, Insights and Forecast – By Indication
- 5.2.1. Acute lymphoblastic leukemia
- 5.2.2. Non-Hodgkin lymphoma
- 5.2.3. Multiple Myeloma
- 5.3. Market Analysis, Insights and Forecast – By End User
- 5.3.1. Hospitals
- 5.3.2. Oncology Treatment Centers
- 5.4. Market Analysis, Insights and Forecast – By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Rest of the World
- 6. North America CAR-T Cell Therapy Market Analysis, Insights and Forecast, 2019-2032
- 6.1. Market Analysis, Insights and Forecast – By Drug Type
- 6.1.1. Axicabtagene Ciloleucel (Yescarta)
- 6.1.2. Brexucabtagene Autoleucel (Tecartus)
- 6.1.3. Ciltacabtagene Autoleucel (Carvykti)
- 6.1.4. Idecabtagene Vicleucel (Abecma)
- 6.1.5. Lisocabtagene Maraleucel (Breyanzi)
- 6.1.6. Tisagenlecleucel (Kymriah)
- 6.1.7. Others
- 6.2. Market Analysis, Insights and Forecast – By Indication
- 6.2.1. Acute lymphoblastic leukemia
- 6.2.2. Non-Hodgkin lymphoma
- 6.2.3. Multiple Myeloma
- 6.3. Market Analysis, Insights and Forecast – By End User
- 6.3.1. Hospitals
- 6.3.2. Oncology Treatment Centers
- 6.4. Market Analysis, Insights and Forecast – By Country
- 6.4.1. U.S.
- 6.4.2. Canada
- 7. Europe CAR-T Cell Therapy Market Analysis, Insights and Forecast, 2019-2032
- 7.1. Market Analysis, Insights and Forecast – By Drug Type
- 7.1.1. Axicabtagene Ciloleucel (Yescarta)
- 7.1.2. Brexucabtagene Autoleucel (Tecartus)
- 7.1.3. Ciltacabtagene Autoleucel (Carvykti)
- 7.1.4. Idecabtagene Vicleucel (Abecma)
- 7.1.5. Lisocabtagene Maraleucel (Breyanzi)
- 7.1.6. Tisagenlecleucel (Kymriah)
- 7.1.7. Others
- 7.2. Market Analysis, Insights and Forecast – By Indication
- 7.2.1. Acute lymphoblastic leukemia
- 7.2.2. Non-Hodgkin lymphoma
- 7.2.3. Multiple Myeloma
- 7.3. Market Analysis, Insights and Forecast – By End User
- 7.3.1. Hospitals
- 7.3.2. Oncology Treatment Centers
- 7.4. Market Analysis, Insights and Forecast – By Country/ Sub-Region
- 7.4.1. U.K.
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Italy
- 7.4.5. Spain
- 7.4.6. Scandinavia
- 7.4.7. Rest of Europe
- 8. Asia Pacific CAR-T Cell Therapy Market Analysis, Insights and Forecast, 2019-2032
- 8.1. Market Analysis, Insights and Forecast – By Drug Type
- 8.1.1. Axicabtagene Ciloleucel (Yescarta)
- 8.1.2. Brexucabtagene Autoleucel (Tecartus)
- 8.1.3. Ciltacabtagene Autoleucel (Carvykti)
- 8.1.4. Idecabtagene Vicleucel (Abecma)
- 8.1.5. Lisocabtagene Maraleucel (Breyanzi)
- 8.1.6. Tisagenlecleucel (Kymriah)
- 8.1.7. Others
- 8.2. Market Analysis, Insights and Forecast – By Indication
- 8.2.1. Acute lymphoblastic leukemia
- 8.2.2. Non-Hodgkin lymphoma
- 8.2.3. Multiple Myeloma
- 8.3. Market Analysis, Insights and Forecast – By End User
- 8.3.1. Hospitals
- 8.3.2. Oncology Treatment Centers
- 8.4. Market Analysis, Insights and Forecast – By Country/ Sub-Region
- 8.4.1. China
- 8.4.2. Japan
- 8.4.3. India
- 8.4.4. Australia
- 8.4.5. Southeast Asia
- 8.4.6. Rest of Asia Pacific
- 9. Rest of the World CAR-T Cell Therapy Market Analysis, Insights and Forecast, 2019-2032
- 9.1. Market Analysis, Insights and Forecast – By Drug Type
- 9.1.1. Axicabtagene Ciloleucel (Yescarta)
- 9.1.2. Brexucabtagene Autoleucel (Tecartus)
- 9.1.3. Ciltacabtagene Autoleucel (Carvykti)
- 9.1.4. Idecabtagene Vicleucel (Abecma)
- 9.1.5. Lisocabtagene Maraleucel (Breyanzi)
- 9.1.6. Tisagenlecleucel (Kymriah)
- 9.1.7. Others
- 9.2. Market Analysis, Insights and Forecast – By Indication
- 9.2.1. Acute lymphoblastic leukemia
- 9.2.2. Non-Hodgkin lymphoma
- 9.2.3. Multiple Myeloma
- 9.3. Market Analysis, Insights and Forecast – By End User
- 9.3.1. Hospitals
- 9.3.2. Oncology Treatment Centers
- 10. Competitive Analysis
- 10.1. Global Market Share Analysis (2023)
- 10.2. Company Profiles
- 10.2.1. Gilead Sciences, Inc.
- 10.2.1.1. Overview
- 10.2.1.2. Products & Services
- 10.2.1.3. SWOT Analysis
- 10.2.1.4. Recent Developments
- 10.2.1.5. Strategies
- 10.2.1.6. Financials (Based on Availability)
- 10.2.2. Novartis AG
- 10.2.2.1. Overview
- 10.2.2.2. Products & Services
- 10.2.2.3. SWOT Analysis
- 10.2.2.4. Recent Developments
- 10.2.2.5. Strategies
- 10.2.2.6. Financials (Based on Availability)
- 10.2.3. Bristol-Myers Squibb Company
- 10.2.3.1. Overview
- 10.2.3.2. Products & Services
- 10.2.3.3. SWOT Analysis
- 10.2.3.4. Recent Developments
- 10.2.3.5. Strategies
- 10.2.3.6. Financials (Based on Availability)
- 10.2.4. Johnson & Johnson Services, Inc. (Janssen Global Services, LLC)
- 10.2.4.1. Overview
- 10.2.4.2. Products & Services
- 10.2.4.3. SWOT Analysis
- 10.2.4.4. Recent Developments
- 10.2.4.5. Strategies
- 10.2.4.6. Financials (Based on Availability)
- 10.2.5. Caribou Biosciences, Inc.
- 10.2.5.1. Overview
- 10.2.5.2. Products & Services
- 10.2.5.3. SWOT Analysis
- 10.2.5.4. Recent Developments
- 10.2.5.5. Strategies
- 10.2.5.6. Financials (Based on Availability)
- 10.2.6. CARsgenTherapeutics Co., Ltd
- 10.2.6.1. Overview
- 10.2.6.2. Products & Services
- 10.2.6.3. SWOT Analysis
- 10.2.6.4. Recent Developments
- 10.2.6.5. Strategies
- 10.2.6.6. Financials (Based on Availability)
- 10.2.7. JW Therapeutics (Shanghai) Co., Ltd.
- 10.2.7.1. Overview
- 10.2.7.2. Products & Services
- 10.2.7.3. SWOT Analysis
- 10.2.7.4. Recent Developments
- 10.2.7.5. Strategies
- 10.2.7.6. Financials (Based on Availability)
- 10.2.8. Cartesian Therapeutics, Inc.
- 10.2.8.1. Overview
- 10.2.8.2. Products & Services
- 10.2.8.3. SWOT Analysis
- 10.2.8.4. Recent Developments
- 10.2.8.5. Strategies
- 10.2.8.6. Financials (Based on Availability)
- 10.2.9. Aurora Biopharma
- 10.2.9.1. Overview
- 10.2.9.2. Products & Services
- 10.2.9.3. SWOT Analysis
- 10.2.9.4. Recent Developments
- 10.2.9.5. Strategies
- 10.2.9.6. Financials (Based on Availability)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook